Interleukin-10 (-1082G/A) Gene Polymorphism in Patients With Type 2 Diabetes With and Without Nephropathy

Basit Öğe Kaydı
dc.contributor.authorErdogan, Mehmet
dc.contributor.authorCetinkalp, Sevki
dc.contributor.authorOzgen, Ahmet Gokhan
dc.contributor.authorSaygili, Fusun
dc.contributor.authorBerdeli, Afig
dc.contributor.authorYilmaz, Candeger
dc.date.accessioned2019-10-27T21:44:37Z
dc.date.available2019-10-27T21:44:37Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Interleukin (IL)-10 is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. IL-10 has met the criteria for an anti-inflammatory and an immunosuppressive cytokine, its activity may be important for clinical outcome of diabetic nephropathy (DN). We aimed at evaluating the relation between the genotypic and allelic frequencies of the IL-10 (-10820/A) polymorphisms, and their association with the risk to develop DN in the Turkish population. Research Design and Methods: The (IL)-10 (-1082G/A) genotypes were retrospectively determined in 43 patients with nephropathy and 48 without nephropathy and a control group of 112 healthy individuals. The polymorphisms were analyzed by polymerase chain reaction restriction fragment length polymorphism. Results: This genotype distribution was different between control subjects and patients with type 2 diabetes in which 24.2% were AA, 75.8% were GA, and 0% were GO (p < 0.001). The frequency of the mutant G allele was 36.1% in patients with diabetes nephropathy versus 39.6% in those without nephropathy (p > 0.05). The genotype frequencies were AA, 27.9%; GA, 72.1%; and GG, 0% in patients with diabetes with nephropathy versus AA, 20.8%; GA, 79.2%; and CC, 0% in those without nephropathy (p > 0.05). Conclusions: The polymorphisms of IL-10 (-10820/A) genes were significantly associated with the occurrence of patients with type 2 diabetes. The IL-10 (-10820/A) genotype and allele frequencies were not different between patients with diabetes with nephropathy and those without nephropathy. Therefore, we conclude that the IL-10 (-10820/A) gene polymorphism is not associated with the development of DN in Turkish patients with type 2 diabetes.en_US
dc.identifier.doi10.1089/gtmb.2011.0075en_US
dc.identifier.endpage94en_US
dc.identifier.issn1945-0265
dc.identifier.issue2en_US
dc.identifier.pmid21861711en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage91en_US
dc.identifier.urihttps://doi.org/10.1089/gtmb.2011.0075
dc.identifier.urihttps://hdl.handle.net/11454/47271
dc.identifier.volume16en_US
dc.identifier.wosWOS:000300591000004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert Incen_US
dc.relation.ispartofGenetic Testing and Molecular Biomarkersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleInterleukin-10 (-1082G/A) Gene Polymorphism in Patients With Type 2 Diabetes With and Without Nephropathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu